Citigroup
KNTE

Citigroup’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Citigroup’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-420,585
Closed -$589K – 5901
2023
Q3 		$589K Buy
420,585
+419,795
+53,139% +$1.01M ﹤0.01% 2941
2023
Q2 		$2.39K Buy
790
+285
+56% +$1.1K ﹤0.01% 5265
2023
Q1 		$3.16K Sell
505
-242
-32% -$1.47K ﹤0.01% 5028
2022
Q4 		$4.56K Sell
747
-206
-22% -$1.68K ﹤0.01% 5052
2022
Q3 		$11K Sell
953
-1,804
-65% -$23.6K ﹤0.01% 4972
2022
Q2 		$35K Sell
2,757
-2,106
-43% -$19.6K ﹤0.01% 4703
2022
Q1 		$55K Sell
4,863
-3,929
-45% -$43.3K ﹤0.01% 4687
2021
Q4 		$156K Buy
8,792
+4,994
+131% +$105K ﹤0.01% 4494
2021
Q3 		$87K Buy
3,798
+2,395
+171% +$52.1K ﹤0.01% 4466
2021
Q2 		$33K Buy
1,403
+408
+41% +$10.4K ﹤0.01% 5036
2021
Q1 		$31K Sell
995
-14,268
-93% -$497K ﹤0.01% 4997
2020
Q4 		$607K Buy
+15,263
New +$612K ﹤0.01% 4029

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citigroup's KNTE Position: Q4 2023 in Review

Citigroup sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2023, closing a stake of 420,585 shares — an estimated $589K sold.

Citigroup first reported a position in KNTE in Q4 2020 and held it in 12 quarters. The position peaked at $607K in Q4 2020. 62 funds tracked by Wall St. Rank hold KNTE as of Q4 2023.

  • Citigroup reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Citigroup sold 420,585 Kinnate Biopharma Inc. Common Stock shares in Q4 2023, an estimated $589K.
  • Citigroup first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 12 quarters.
  • Citigroup's Kinnate Biopharma Inc. Common Stock position peaked at $607K in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2023.

Based on Citigroup's 13F filing for Q4 2023, filed 9 Feb 2024.